DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Clywedog Therapeutics, Inc., a clinical-stage biotechnology company advancing novel therapies for metabolic diseases, today announced the activation of all ...
GERMANTOWN, Md. - Barinthus Biotherapeutics plc (NASDAQ:BRNS) announced Wednesday that its experimental celiac disease treatment VTP-1000 showed promising results in the initial portion of its first ...
Single ascending dose data readout for VTP-1000 expected before the end of 2025 Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026 ...
SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Barinthus Biotherapeutics ( (BRNS)) has ...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback